drugset / Trial / NCT03499704
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 26.
Timeline
- Start
- 2020-02-11
- Primary completion
- 2024-01-02
- Completion
- 2024-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |
| Subject | Pioglitazone | Small molecule | 15 mg | Oral |
| Subject | Pioglitazone | Small molecule | 30 mg | Oral |
| Comparator | Alogliptin | Unknown | 25 mg | Oral |
| Background | Metformin | Small molecule | 500 mg | Oral |